Von Willebrand disease (VWD) is a complex bleeding disorder with a wide range of clinical presentations and genetic variations. It is caused by reduced levels or activity of von Willebrand factor (VWF), leading to a variety of bleeding phenotypes. The disease is classified into three main types: Type 1, Type 2, and Type 3, each with distinct characteristics and inheritance patterns. The prevalence of VWD varies globally, influenced by factors such as diagnostic criteria, population genetics, and clinical presentation.
Classification and Epidemiology:
VWD is categorized into Type 1 (60-70% of cases), Type 2 (20-25% of cases), and Type 3 (5% of cases). Type 1 is characterized by partial quantitative VWF deficiency, while Type 2 involves qualitative defects in VWF. Type 3 is marked by the absence of VWF and low factor VIII (FVIII) levels. The inheritance patterns differ: Type 1 is autosomal dominant, Type 2 is often dominant with high penetrance, and Type 3 is autosomal recessive.
The prevalence of VWD is estimated to be around 1%, but accurate diagnosis can be challenging due to various confounding factors. The actual prevalence of clinically significant cases is uncertain, and it varies based on diagnostic criteria and patient populations. For instance, hospital-based studies may yield lower prevalence rates compared to population-based studies.
Clinical Phenotypes and Classification:
VWD patients exhibit excessive mucocutaneous bleeding, including epistaxis, gum bleeding, heavy menstrual bleeding, and gastrointestinal bleeding. The severity of bleeding tends to increase across different types. Type 1 VWD with VWF levels above 30 U/dL is typically mild, but females experience more frequent bleeding episodes due to menstruation and childbirth. Women with VWD often have a lower quality of life due to chronic anemia and increased bleeding during childbearing.
Epidemiological Data:
The prevalence of VWD in the general population is estimated to be around 1%, but accurate diagnosis can be challenging. Studies using self-report questionnaires have found that about 25% of Swedish girls reported three or more hemorrhagic symptoms, while physician-guided questionnaires identified less than 1% of normal controls. Stringent criteria and clinical expertise are essential for accurate assessment.
Prevalence by Type:
- Type 3 VWD is rare, with a prevalence ranging from 0.1 to 5.3 per million. It is more common in certain populations, such as Arabs with a high rate of consanguinity.
- Type 1 VWD is the most prevalent, with a wide range of VWF levels. The prevalence of severe Type 1 VWD (VWF level <10 U/dL) could be higher than previously thought.
- Type 2 VWD is less common but has various subtypes, each with distinct pathophysiological mechanisms and laboratory features.
Genetic Insights:
Recent genetic studies have revealed that pathogenic VWF variants are more prevalent than initially estimated, producing a full range of VWD phenotypes. The global prevalence of dominant VWD types is estimated to be 7.4% for Type 1, 0.3% for Type 2A, 0.3% for Type 2B, and 0.6% for Type 2M. For recessive forms, the prevalence is 0.03% for Type 3 and 0.07% for Type 2N.
Current Perspectives:
VWD remains a challenging disorder to diagnose and manage, especially in low-income countries where clinical cases may be undiagnosed or unreported. There is a need for improved access to diagnosis, standardized reporting, and clinical prospective observations to determine the frequency and severity of bleeding events, particularly in patients with moderate and mild VWD.
